CSIMarket Company Name, Ticker, Customers, else..
 
Qualigen Therapeutics Inc   (NASDAQ: QLGN)
Other Ticker:  
 
 
Price: $4.3650 $0.09 1.986%
Day's High: $4.365 Week Perf: -3.64 %
Day's Low: $ 4.28 30 Day Perf: -14.07 %
Volume (M): 4 52 Wk High: $ 32.85
Volume (M$): $ 20 52 Wk Avg: $14.58
Open: $4.28 52 Wk Low: $3.34



 Market Capitalization (Millions $) 33
 Shares Outstanding (Millions) 8
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Qualigen Therapeutics Inc
Qualigen Therapeutics Inc. is a biotechnology company that focuses on the development of innovative therapeutic products for the treatment of various diseases and conditions. The company is dedicated to advancing its pipeline of potential products, including cancer treatments, infectious disease diagnostics, and novel drug delivery techniques. Qualigen Therapeutics aims to improve patient outcomes and advance the field of medicine through its cutting-edge research and development efforts.


   Company Address: 5857 Owens Avenue, Suite 300 Carlsbad 92008 CA
   Company Phone Number: 452-8111   Stock Exchange / Ticker: NASDAQ QLGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -3.7%    
JNJ   -1.93%    
LLY   -3.48%    
MRK   -3.67%    
TEVA   -2.58%    
VTRS   -4.06%    
• View Complete Report
   



Qualigen Therapeutics Inc

Lackluster revenue at the Qualigen Therapeutics Inc in the most recent fiscal period

Qualigen Therapeutics Inc stock has seen some fluctuations in recent trading days. However, over the last five trading days, the stock experienced a solid gain of 7.2%. This positive movement comes after a slight decline of -1.91% during the preceding month.
Investors may also note that Qualigen Therapeutics Inc stock is currently trading only 12.3% above its 52-week low. This suggests that the stock has not seen significant upward momentum in recent months.
Qualigen Therapeutics Inc

Qualigen Therapeutics Inc Sees Promising Revenue Growth in Q2, But Profitability Remains Elusive

Interpreting the financial results of Qualigen Therapeutics Inc, it is evident that there have been both positive and negative developments in the company's performance. While revenue increased by a significant 13.736% compared to the previous year, losses also expanded at a rate of $-0.69 deficit per share. These contrasting results indicate a need for analysis and understanding of the underlying factors that contributed to these outcomes.
Looking at recent numbers from the previous reporting season, revenue continued to grow by 1.236% from $1.61 million. Moreover, there was an improvement in income per share from $-0.78 per share. This indicates that the company is making headway in terms of generating revenue and potentially improving profitability.
Qualigen Therapeutics Inc

Biotech Company, Qualigen Therapeutics, Shows Impressive Revenue Growth Amidst Financial Concerns

Qualigen Therapeutics Inc, a biotechnology company involved in the development of novel cancer treatment solutions, has reported very strong revenue growth of 122.591% YoY to $1.61 million in the fiscal year ending March 31, 2023. However, the company has also reported an increased shortfall per share at $-0.78, which is a worry for investors and indicates that the company may be experiencing some financial difficulties.
Despite this, revenue improved by 15.63% from $1.39 million in the preceding quarter. The fiscal first quarter of 2023 saw Qualigen Therapeutics Inc report a net shortfall of $-4.107 million, instead of the deficit of $-4.320 million recorded in the corresponding quarter a year ago.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com